CYBERNA

Specializes in diagnostic platforms that license patented chemical modifications of RNA as biomarker signatures for early cancer detection. Its multiplex technology combines mass spectrometry and machine learning to deliver scalable, low-cost solutions for in vitro diagnostic medical device partners.